The targets that improved overall survival in sarcoma patients when gene expression was downregulated included Cyclin-dependent kinase 1 (CDK1), mitogen-activated protein kinase (MAPK1), Mitogen-activated protein kinase 14 (MAPK14), Mitogen-activated protein kinase 8 (MAPK8), Myc proto-oncogene protein (MYC), Peroxisome proliferator-activated receptor gamma (PPARG), and PRKCA-binding protein (PRKCA). Here, PRKCA is linked to sarcoma.